Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

doi:10.1158/1078-0432.CCR-25-0650

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2026

Bianchini Giampaolo, Malorni Luca, Caputo Roberta, Zambelli Alberto, Puglisi Fabio, Bianchi Giulia V, Del Mastro Lucia, Paris Ida, Montemurro Filippo, Colleoni Marco, Allegrini Giacomo, Tamberi Stefano, Zamagni Claudio, Cazzaniga Marina E, Orditura Michele, Guarneri Valentina, Adamo Vincenzo, Romagnoli Emanuela, Valerio Maria Rosaria, Cinieri Saverio, Benelli Matteo, Callari Maurizio, Valsecchi Diletta, Castelletti Daniela, Grasso Donatella, Fenderico Nicola, Arpino Grazia, De Laurentiis Michelino

Abstract excerpt

PURPOSE: This phase IIIb study prospectively evaluated the prognostic and predictive value of baseline and dynamic circulating tumor DNA (ctDNA) in postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with first-line ribociclib/letrozole. EXPERIMENTAL DESIGN: A total of 287 patients were enrolled, with ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminopyridines

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Purines

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 41587113
DOI: 10.1158/1078-0432.CCR-25-0650
PMCID: PMC13266340

Genes

TP53
MYC
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.PMID 41587113Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudySemantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Circulating tumor DNA in breast cancer: a biomarker for patient selection.Semantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.Semantic proximity Read ↗

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.Semantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.